Trial · NCT02513550
Participant flow42
How many started, completed or left each group, period by period.
1 to 20 of 42
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Double Blind Treatment Period | STARTED | 80 mg Ixekizumab Q4W | 310 | |
| Double Blind Treatment Period | STARTED | 80 mg Ixekizumab Q4W/Q2W | 306 | |
| Double Blind Treatment Period | STARTED | 80 mg Ixekizumab Q2W | 611 | |
| Double Blind Treatment Period | STARTED | 80 mg Ixekizumab Q4W Maximum Extended Enrollment Cohort | 9 | |
| Double Blind Treatment Period | STARTED | 80 mg Ixekizumab Q4W/Q2W Maximum Extended Enrollment Cohort | 5 | |
| Double Blind Treatment Period | STARTED | 80 mg Ixekizumab Q2W Maximum Extended Enrollment Cohort | 16 | |
| Double Blind Treatment Period | Received at Least One Dose of Study Drug | 80 mg Ixekizumab Q4W | 310 | |
| Double Blind Treatment Period | Received at Least One Dose of Study Drug | 80 mg Ixekizumab Q4W/Q2W | 306 | |
| Double Blind Treatment Period | Received at Least One Dose of Study Drug | 80 mg Ixekizumab Q2W | 609 | |
| Double Blind Treatment Period | Received at Least One Dose of Study Drug | 80 mg Ixekizumab Q4W Maximum Extended Enrollment Cohort | 9 | |
| Double Blind Treatment Period | Received at Least One Dose of Study Drug | 80 mg Ixekizumab Q4W/Q2W Maximum Extended Enrollment Cohort | 5 | |
| Double Blind Treatment Period | Received at Least One Dose of Study Drug | 80 mg Ixekizumab Q2W Maximum Extended Enrollment Cohort | 16 | |
| Double Blind Treatment Period | COMPLETED | 80 mg Ixekizumab Q4W | 274 | |
| Double Blind Treatment Period | COMPLETED | 80 mg Ixekizumab Q4W/Q2W | 268 | |
| Double Blind Treatment Period | COMPLETED | 80 mg Ixekizumab Q2W | 537 | |
| Double Blind Treatment Period | COMPLETED | 80 mg Ixekizumab Q4W Maximum Extended Enrollment Cohort | 9 | |
| Double Blind Treatment Period | COMPLETED | 80 mg Ixekizumab Q4W/Q2W Maximum Extended Enrollment Cohort | 4 | |
| Double Blind Treatment Period | COMPLETED | 80 mg Ixekizumab Q2W Maximum Extended Enrollment Cohort | 15 | |
| Double Blind Treatment Period | NOT COMPLETED | 80 mg Ixekizumab Q4W | 36 | |
| Double Blind Treatment Period | NOT COMPLETED | 80 mg Ixekizumab Q4W/Q2W | 38 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02513550/flow